A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Part of paid clinical trials in Upland, California.
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Study ID
- NCT07355218
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Cutaneous Lupus Erythematosus
- Systematic Lupus Erythematosus
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Enpatoran — DRUGParticipants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.
- Placebo — DRUGParticipants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.
- Standard of care (SoC) — DRUGParticipants will receive Investigator-recommended SoC.
Study Details
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Key Dates
- Start date
- Apr 1, 2026
- Status verified
- May 2026
- Primary completion
- May 25, 2029
- Completion
- May 25, 2029
Study Design
- Enrollment
- 202 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Enpatoran
- Placebo Comparator: Placebo
Primary Outcome Measure
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From Baseline [ Time Frame: At Week 24 ]
Central Contacts
- US Medical Information888-275-7376
- Communication Center+49 6151 72 5200
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Inland Rheumatology Clinical Trials, Inc. | Upland | California | 91786 | - |
| Omega Research Debary, LLC | DeBary | Florida | 32713 | - |
| Bolanos Clinical Research | Pembroke Pines | Florida | 33026 | - |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | - |
Find similar trials in Upland, CA
Related Studies
- Tapinarof for Cutaneous Lupus ErythematosusEARLY_PHASE1 · Enrolling By Invitation · Northwestern University · Chicago, Illinois